Swiss-based pharma group to produce Sputnik vaccine in Italy
The Lugano-headquartered Adienne pharma company has agreed to produce the Russian Sputnik V Covid-19 vaccine in its northern Italy plant, the Italian-Russian chamber of commerce has said.
This content was published on
2 minutes
Reuters/AFP/dos
Español
es
Firma con sede en Suiza produciría la Sputnik V en Italia
If the agreement between the Russia’s RDIF sovereign wealth fund – which markets Sputnik internationally – and Adienne is approved by Italian authorities, production in Italy could begin in June. The hope is to produce some 10 million doses of the vaccine by the end of 2021, the chamber of commerce said on Tuesday. It would be the first Sputnik V production facility in Europe.
Vincenzo Trani, the head of the chamber of commerce, said “it can be called a historic event, which is proof of the good state of relations between our countries and shows that Italian companies can see beyond political differences”.
Adienne is headquartered in Lugano, in southern Switzerland, but operates manufacturing plants in the northern Italian region of Lombardy.
Sputnik V is being reviewed by European Union regulators but has not been approved for use in the bloc. Russia has complained that the EU keeps pushing back the approval process, while acknowledging that the vaccine is already authorised in 46 countries worldwide.
More
More
How vaccine technology, choice and supply work in Switzerland
This content was published on
The Swiss Covid-19 vaccination campaign is up and running. How do the vaccine technologies work and compare?
A spokesman for the Italian-Russian chamber of commerce told the AFP news agency Tuesday that “if the vaccine is not authorised in Europe by July 1, 2021, then the doses produced [in Italy] will be bought back by the Russian sovereign wealth fund and distributed to countries where it is approved”.
The EU has approved three vaccines to date: from Pfizer/BioNTech, Moderna, and AstraZeneca. However, the vaccine rollout in the bloc has stumbled after production delays led to a shortfall in expected vaccine deliveries.
Last week, Italy blocked the export of 250,000 doses of the Oxford/AstraZeneca vaccine to Australia in an ongoing row between the EU and the UK-based pharma company.
Switzerland has so far approved – and is administering – two of the vaccines, from Pfizer and Moderna. However, it has also preordered batches from AstraZeneca, CureVac, and Novavax.
While not at the forefront in developing vaccines, Swiss companies have been stepping up their involvement in manufacturing Covid-19 vaccines. Lonza is producing ingredients for the Moderna vaccine at its production plant in Visp, southern Switzerland, while pharma giant Novartis has signed deals to help manufacture both the Pfizer/BioNtech and CureVac vaccines.
More
More
Novartis to help produce CureVac Covid-19 vaccine
This content was published on
Novartis has signed an initial deal to produce the mRNA molecules for the Covid-19 vaccine developed by German biotech firm CureVac.
Ecological status of Swiss streams insufficient according to study
This content was published on
Pesticide use and obstructions of waterways have a particularly negative impact on sensitive organisms, completely absent in 70% of streams analysed.
Train line between Brig and Domodossola interrupted
This content was published on
One day after a derailment approximately 15 kilometres from the Swiss border, BLS is running buses for passengers between Preglia and Domodossola, in Italy.
Swiss football boss wants crackdown on individual hooligans
This content was published on
The head of the Swiss Football League says he prefers a harsher approach to individual hooligans rather than collective punishment measures affecting all fans.
Amherd: Council of Europe is ‘as urgently needed as ever’
This content was published on
The Swiss government emphasised on Sunday the vital role of the Strasbourg-based Council of Europe, 75 years after it was founded.
Swiss minister: Italy will back Switzerland in EU talks
This content was published on
Bern can count on the backing of Italy as it re-enters talks with the European Union on future relations, Viola Amherd says.
Student protestors at University of Lausanne continue pro-Palestine sit-in
This content was published on
Since Thursday, a hall on campus has been occupied by students calling for a boycott of Israeli academic institutions and a ceasefire in Gaza.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis agrees to help Pfizer-BioNTech produce Covid-19 vaccine
This content was published on
Swiss pharma giant Novartis says it has signed an initial agreement to provide manufacturing capacity for Pfizer and BioNTech's Covid-19 vaccine.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.